Cargando…
Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells
Background. mTOR signaling would be a promising target for thyroid cancer therapy. However, in clinical trials, objective response rate with mTOR inhibitor monotherapy in most cancer types was modest. A new focus on development of combinatorial strategies with rapalogs is increasing. Objective. Inve...
Autores principales: | Zhou, Jun, He, Li-Li, Ding, Xiao-Fei, Yuan, Qiu-Qi, Zhang, Jian-Xin, Liu, Shuang-Chun, Chen, Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870352/ https://www.ncbi.nlm.nih.gov/pubmed/27274989 http://dx.doi.org/10.1155/2016/6723807 |
Ejemplares similares
-
13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-β-elemene, a novel β-elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells
por: DING, XIAO-FEI, et al.
Publicado: (2013) -
The Antitumor Efficacy of β-Elemene by Changing Tumor Inflammatory Environment and Tumor Microenvironment
por: Xie, Qiang, et al.
Publicado: (2020) -
Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor
por: Wu, Dawei, et al.
Publicado: (2018) -
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy
por: Zhai, Bingtao, et al.
Publicado: (2018) -
β-elemene combined with temozolomide in treatment of brain glioma
por: Zhang, Xiaomin, et al.
Publicado: (2021)